Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
1 clinical trials · Condition
◉ Watch Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
| Record | Firm | Date |
|---|---|---|
| An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases (NCT04339829) | Guangdong Association of Clinical Trials | 2020-08-01 |
Track Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases automatically
Every clearance here is in the API, with alerts when new ones post.